About US
Contact us
-
Chugai Pharmaceutical to build new $1bn research lab in JapanChugai Pharmaceutical has revealed plans to establish a core research laboratory at its business site in Yokohama, Kanagawa Prefecture, Japan. Named Chugai Life Science Park Yokohama, the new facilit2019/5/27
-
Janssen’s Invokana secures FDA priority review statusJanssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney dise2019/5/27
-
Novartis CEO says Zolgensma won't cost anywhere near the $4M to $5M once quotedNovartis has said its forthcoming spinal muscular atrophy gene therapy could be cost-effective at a price of up to $5 million, but now the company's CEO says to think "far lower." As the Swiss drug2019/5/24
-
Array's ‘extremely compelling’ new colon cancer data spark blockbuster talkThe news that Array BioPharma’s clinical trial of its triplet therapy for colon cancer extended lives in a trial of patients with the BRAF mutation sent the company’s shares up 23% on Tuesday—a run t2019/5/24
-
GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle ChinaGlaxoSmithKline’s shingles vaccine Shingrix has continuously impressed industry watchers with its explosive growth. Now, the company has added another large market to its list:China. Shingrix has bee2019/5/23
-
J&J, in rebuttal to pricing criticism, says antidepressant Spravato is cost-effectiveDays ago, Johnson & Johnson’s controversial nasal depression drug Spravato was criticized as being too pricey. In response, the company has now come up with its own study to champion the drug’s c2019/5/23
-
Merck's powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new useRight now, Roche’s Tecentriq is the only immuno-oncology drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile. Merck's steamroller Keytruda turned in a rar2019/5/22
-
Hurting for revenue, Mylan shells out $130M for basket of Aspen drugsWith share prices tumbling and a massive drug-price fixing lawsuit hanging over its head, Mylan’s future is looking increasingly spooky. Could a modest acquisition help turn the tide? It's willing to2019/5/22
-
Lawmakers clash as Gilead CEO takes congressional hot seat to defend TruvadaGilead Sciences' important HIV business has been under fire in recent weeks, with lawsuits and critics airing allegations about the company’s pricing, patents and more. On Thursday, the company’s n2019/5/21
-
After Oklahoma payout, Purdue faces 5 new state lawsuits over OxyContinPurdue Pharma and its founding family took a quarter-of-a-billion-dollar hit when it settled with the state of Oklahoma over a lawsuit accusing the company of pushing false and misleading ads for pow2019/5/21